Evidence over the years has shown IL-17 and IL-36 cooperate to drive skin inflammation (27, 37, 38, 42, 44, 45), however there is no therapeutic agent currently available targeting both IL-17 and IL-36. This evidence concerns the gene IL17A and dermatitis.